Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if XENE is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
63 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: buy 14 days ago
Red flags: 1
316 filers reported a long position in XENE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $582.4M | 9.6M | -10.8% |
| BlackRock, Inc. | $454.1M | 7.5M | +33.4% |
| Avoro Capital Advisors LLC | $348.7M | 5.8M | Unchanged |
| Polar Capital Holdings Plc | $275.9M | 4.6M | +3.8% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $266.7M | 4.4M | -1.6% |
| Jupiter Topco LLC | $252.7M | 4.2M | — |
| PRICE T ROWE ASSOCIATES INC /MD/ | $196.1M | 3.2M | +144.3% |
| JPMORGAN CHASE & CO | $157.4M | 2.6M | +36.1% |
| Capital International Investors | $142.5M | 2.4M | -11.7% |
| T. Rowe Price Investment Management, Inc. | $130.9M | 2.2M | +127.8% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.